Tharimmune ' s Oral ' Under The Cheek ' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease

Tuesday, Tharimmune Inc THAR completed its Phase 1 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene, which easily adheres inside of the mouth on the cheek and biodegrades within minutes. TH104 is designed to avoid the liver’s…#tharimmuneincthar #phase1 #th104 #fda #tharimmune #thar
Source: Reuters: Health - Category: Consumer Health News Source Type: news